Výsledky vyhledávání - "Jess W. Hoag"

BRAF mutation classes and co-occurring mutations in NSCLC

Autor: Jiaxin Niu, Cynthia A. Flannery, David W. Hall, Jess W. Hoag, Nishitha Therala, Ariane C. Kemkes, Josh Routh, Jean-Paul De La O, Lisa Macera, Snehal Govind Thakkar

Publikováno v: Journal of Clinical Oncology. 40:9083-9083

9083 Background: Targeted therapy against unique molecular drivers has revolutionized non-small cell lung cancer (NSCLC) treatment. BRAF mutations, present in 2%-5%, have emerged as therapeutic targets, and can be divided into three classes: kinase-a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d19c2a7ab012aa5383ee3eb3b94c0aa
https://doi.org/10.1200/jco.2022.40.16_suppl.9083

Zobrazit plný text záznamu

Comprehensive genomic profiling to identify gene alterations in DNA repair pathway across solid tumors

Autor: Kevin McDonnell, Gargi D. Basu, Jess W. Hoag, David W. Hall, Fadel S. Alyaqoub, Susan M. Dombrowski, Pawan Noel, Szabolcs Szelinger, Sameer S. Udhane, Min Wang, Janine R. LoBello, Snehal Govind Thakkar, Frederick L. Baehner, Christine Hong, Wai Park, Gregory Idos, Stacy W. Gray, Stephen B. Gruber

Publikováno v: Journal of Clinical Oncology. 40:3124-3124

3124 Background: Deleterious events in DNA damage response (DDR) are hallmarks of cancer associated with sensitivity to PARP inhibitors (PARPi) and immune checkpoint inhibitors (CPI). This study investigated DDR pathway alterations across solid tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::57d09da0f0e1f365ecde60377964efe6
https://doi.org/10.1200/jco.2022.40.16_suppl.3124

Zobrazit plný text záznamu

Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer

Autor: Susan M. Dombrowski, Sameer S. Udhane, Gargi D. Basu, David W. Hall, Jess W. Hoag, Fadel S. Alyaqoub, Pawan Noel, Szabolcs Szelinger, Min Wang, Audrey A. Ozols, Janine R. LoBello, Snehal Govind Thakkar, Frederick L. Baehner, Joyce O'Shaughnessy

Publikováno v: Journal of Clinical Oncology. 40:1096-1096

1096 Background: The use of targeted therapies identified using genetic and genomic approaches is now routine in breast cancer (BC). In this clinical lab experience study the frequency of actionable somatic alterations in DNA repair pathway genes ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46c21ce22c8fbaa421b50d5560d70351
https://doi.org/10.1200/jco.2022.40.16_suppl.1096

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání